NuCana PLC
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.6054
- Today's High:
- $0.631
- Open Price:
- $0.63
- 52W Low:
- $0.59
- 52W High:
- $1.75
- Prev. Close:
- $0.644
- Volume:
- 30791
Company Statistics
- Market Cap.:
- $33.75 million
- Book Value:
- 0.528
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -43.99%
- Return on Equity TTM:
- -79.14%
Company Profile
NuCana PLC had its IPO on 2017-09-28 under the ticker symbol NCNA.
The company operates in the Healthcare sector and Biotechnology industry. NuCana PLC has a staff strength of 28 employees.
Stock update
Shares of NuCana PLC opened at $0.63 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.61 - $0.63, and closed at $0.62.
This is a -3.93% slip from the previous day's closing price.
A total volume of 30,791 shares were traded at the close of the day’s session.
In the last one week, shares of NuCana PLC have slipped by -3.33%.
NuCana PLC's Key Ratios
NuCana PLC has a market cap of $33.75 million, indicating a price to book ratio of 0.6476 and a price to sales ratio of 0.
In the last 12-months NuCana PLC’s revenue was $0 with a gross profit of $0 and an EBITDA of $-37735000. The EBITDA ratio measures NuCana PLC's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, NuCana PLC’s operating margin was 0% while its return on assets stood at -43.99% with a return of equity of -79.14%.
In Q2, NuCana PLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
NuCana PLC’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.73 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NuCana PLC’s profitability.
NuCana PLC stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.4787. Its price to sales ratio in the trailing 12-months stood at 0.
NuCana PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $41.26 million
- Total Liabilities
- $13.54 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $137000
- Dividend Payout Ratio
- 0%
NuCana PLC ended 2024 with $41.26 million in total assets and $0 in total liabilities. Its intangible assets were valued at $41.26 million while shareholder equity stood at $27.38 million.
NuCana PLC ended 2024 with $0 in deferred long-term liabilities, $13.54 million in other current liabilities, 2097000.00 in common stock, $-193540000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $24.64 million and cash and short-term investments were $24.64 million. The company’s total short-term debt was $286,000 while long-term debt stood at $0.
NuCana PLC’s total current assets stands at $37.89 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $10.65 million compared to accounts payable of $4.68 million and inventory worth $0.
In 2024, NuCana PLC's operating cash flow was $0 while its capital expenditure stood at $137000.
Comparatively, NuCana PLC paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.62
- 52-Week High
- $1.75
- 52-Week Low
- $0.59
- Analyst Target Price
- $4.38
NuCana PLC stock is currently trading at $0.62 per share. It touched a 52-week high of $1.75 and a 52-week low of $1.75. Analysts tracking the stock have a 12-month average target price of $4.38.
Its 50-day moving average was $0.74 and 200-day moving average was $0.97 The short ratio stood at 1.86 indicating a short percent outstanding of 0%.
Around 71.6% of the company’s stock are held by insiders while 3131.4% are held by institutions.
Frequently Asked Questions About NuCana PLC
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil, which is in a Phase 1b/2 study in patients with metastatic colorectal cancer. The company also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer; and initiated a Phase 1b/2 modular study of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. Its pipeline also comprises NUC-7738, a transformation of 3′-deoxyadenosine that is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.